{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:23:29Z","timestamp":1761855809384,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004634","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004634","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Study, Education, and Research Committee (SERC)"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.pathol.2018.08.009","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T12:20:53Z","timestamp":1541161253000},"page":"748-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Activity of ceftolozane\/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia"],"prefix":"10.1016","volume":"50","author":[{"given":"A.","family":"Henderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2018.08.009_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bjid.2017.03.006","article-title":"Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015","volume":"21","author":"Karlowsky","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.pathol.2018.08.009_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5604\/17331331.1197272","article-title":"Effectiveness of antipseudomonal antibiotics and mechanisms of multidrug resistance in Pseudomonas aeruginosa","volume":"65","author":"El","year":"2016","journal-title":"Pol J Microbiol"},{"key":"10.1016\/j.pathol.2018.08.009_bib3","doi-asserted-by":"crossref","first-page":"e0176774","DOI":"10.1371\/journal.pone.0176774","article-title":"Molecular epidemiological survey of bacteremia by multidrug resistant Pseudomonas aeruginosa: the relevance of intrinsic resistance mechanisms","volume":"12","author":"Dantas","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2018.08.009_bib4","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1086\/504477","article-title":"Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa","volume":"43","author":"Bonomo","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2018.08.009_bib5","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/AAC.01645-10","article-title":"Spanish Network for Research in Infectious Diseases. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study","volume":"55","author":"Cabot","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib6","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1128\/AAC.00503-07","article-title":"Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections","volume":"51","author":"Hocquet","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jgar.2018.02.005","article-title":"Risk factors for Pseudomonas aeruginosa infections consequences of inappropriate initial antimicrobial therapy: a systematic literature review meta-analysis","volume":"14","author":"Merchant","year":"2018","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.pathol.2018.08.009_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.amjmed.2003.07.005","article-title":"Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis","volume":"115","author":"Harbarth","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.pathol.2018.08.009_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s10096-008-0568-5","article-title":"Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia","volume":"27","author":"Cheong","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"year":"2016","series-title":"Zybaxa (ceftolozane\/tazobactam). (Package insert)","key":"10.1016\/j.pathol.2018.08.009_bib10"},{"key":"10.1016\/j.pathol.2018.08.009_bib11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in\u00a0vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib12","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/AAC.00680-12","article-title":"Pan-beta-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities","volume":"56","author":"Moya","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.pathol.2018.08.009_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.pathol.2018.08.009_bib15","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib16","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US Hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib17","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters, Version 8.0. Cited 15 Mar 2018. http:\/\/www.eucast.org."},{"year":"2018","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100","key":"10.1016\/j.pathol.2018.08.009_bib18"},{"key":"10.1016\/j.pathol.2018.08.009_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2018.08.009_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jgar.2017.05.025","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: report from an antimicrobial surveillance program (2013-2015)","volume":"10","author":"Pfaller","year":"2017","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.pathol.2018.08.009_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02136-16","article-title":"Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections","volume":"61","author":"Caston","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40121-016-0104-3","article-title":"Successful treatment of multi-drug resistant Pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane\/tazobactam regimen","volume":"5","author":"Patel","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.pathol.2018.08.009_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pathol.2018.08.009_bib24","article-title":"Mechanisms leading to in\u00a0vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","author":"Fraile-Ribot","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane-tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pathol.2018.08.009_bib26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/JCM.01920-16","article-title":"Comparison of Etest to broth microdilution for testing of susceptibility of Pseudomonas aeruginosa to ceftolozane-tazobactam","volume":"55","author":"Flynt","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.pathol.2018.08.009_bib27","first-page":"239","article-title":"Colistin and polymyxin B minimal inhibitory concentrations determined by Etest found unreliable for Gram-negative bacilli","volume":"17","author":"Simar","year":"2017","journal-title":"Ochsner J"},{"key":"10.1016\/j.pathol.2018.08.009_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/JCM.02128-16","article-title":"Improved accuracy of cefepime susceptibility testing for extended-spectrum-beta-lactamase-producing Enterobacteriaceae with an on-demand digital dispensing method","volume":"55","author":"Smith","year":"2017","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.pathol.2018.08.009_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01633-17","article-title":"Performance of ceftolozane-tazobactam Etest, MIC test strips, and disk diffusion compared to reference broth microdilution for beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"56","author":"Humphries","year":"2018","journal-title":"J\u00a0Clin Microbiol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130251830196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130251830196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:23:37Z","timestamp":1758471817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003130251830196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S003130251830196X"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2018.08.009","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of ceftolozane\/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}